ClinicalTrials.gg
RecruitingNCT07692217Updated Sep 29, 2026

TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies

An observational study in Hemophilia A and Factor VIII (FVIII), sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Texas Southwestern Medical Center · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Hemophilia A with a site in United States — 40 open to participants now, 59 under way, 17 of them phase 3. Hemophilia A · United States.

Planned enrollment
42nd of 75
60 · median 72
Started
2026
with 13 others
Observational
75 of 299
16 open now
Primary completion
2033-05
later than 53 of 58 live
Registered
296th of 299
by date

Among the 299 studies in Hemophilia A with a site in United States, this one is the 42nd largest by planned enrollment of the 75 observational ones that give a count, is one of 14 that started in 2026, is one of 75 observational ones, reaches primary completion later than 53 of the 58 other live ones, and was the 296th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

40 of the 299 studies in Hemophilia A with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Hemophilia A with a site in United States, or all of them as a file.
02

Study summary

This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII.

Read the detailed description

This research study aims to compare the differences in the way children with moderate or severe hemophilia A respond when being treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) vs non-FVIII based replacement therapy (such as Hemlibra) as part of their hemophilia treatment to prevent spontaneous joint bleeds. This study will collect information about the patient's joint health, patient outcomes (using questionnaires), and laboratory testing at specific time points over 3 years.

The study will use an overall approach of comparative effectiveness research (CER) methodology. The investigators plan to recruit participants with severe (FVIII \<1%) and moderate (FVIII 1-4%) HA who take extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy as their clinically prescribed treatment. Both are standard of care treatment for persons with Hemophilia A (PwHA). Using CER principals, this study will analyze differences in 1) hemostatic potential and annualized bleeding rates (Aim 1-3) and 4) joint health (structural and functional) using the Hemophilia Joint Health Score (HJHS) and imaging markers to identify subclinical bleeding and early joint tissue changes in PwHA on novel FVIII and non-FVIII therapies already in use in practice (Aim 4). The proposed study will be the first systematic observational comparative effectiveness study in PwHA on two conventional, standard-of-care novel therapies with differing mechanisms of action to evaluate the overall effectiveness of treatment.

03

Conditions studied

  • Hemophilia A
  • Factor VIII (FVIII)

Browse trials for

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  • Children (defined as persons who have not attained the legal age for consent to treatments or procedures involved in the research, under the applicable law of the jurisdiction in which the research will be conducted. In Texas the legal age is 18.)
  • Non-English Speakers
  • Patients (defined as individuals in a clinical setting with whom there is a treatment relationship)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderate or severe HA who are on prophylaxis with either weekly, biweekly, or every 4-weeks emicizumab or weekly efanesoctocog alfa for at least 2 months.
  • >6 months of age

Exclusion criteria

Exclusion Criteria:

  • Participants with active FVIII inhibitor (>0.5 BU/mL)
  • Presence of an additional bleeding disorder other than hemophilia A
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants with hemophilia A

    The study plans to recruit participants with severe (FVIII \<1%) and moderate (FVIII 1-4%) HA.

    Drug: Half-life factor VIII based replacement therapy · Drug: Non-FVIII based replacement therapy

Interventions

  • Children with moderate or severe hemophilia A being treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) as part of their hemophilia treatment to prevent spontaneous joint bleeds.

    Also known as: Altuviiio

  • Children with moderate or severe hemophilia A being treated with non-FVIII based replacement therapy (such as Hemlibra) as part of their hemophilia treatment to prevent spontaneous joint bleeds.

    Also known as: Hemlibra

06

What researchers measure

Primary outcomes

  1. Thrombin Generation

    To determine and compare in vivo thrombin generation parameters; endogenous thrombin potential (ETP) and peak thrombin (PT) for patients on efanesoctocog alfa or emicizumab

    Time frame: Thrombin generation assay will be measured at 5 time points within a week of receiving dose of medication

  2. Hemophilia Joint Health Score

    To obtain and compare HJHS in patients on efanesoctocog alfa or emicizumab

    Time frame: Obtained at baseline and every 6 months, until 3 years

Secondary outcomes

  1. Annualized bleeding rate

    To collect bleeding episodes in study participants and to calculate their respective total, treated, and joint annualized bleeding rates

    Time frame: From enrollment, every 6 months, until 3 years

  2. Health related quality of life - CHO-KLAT

    Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) will be used to evaluate the impact of different treatment strategies. CHO-KLAT will be obtained and compared in study participants on efanesoctocog alfa or emicizumab.

    Time frame: From enrollment, every 6 months, until 3 years

  3. Health related quality of life - PedHAL

    PedHAL is a validated patient-reported outcome measure designed to assess self-perceived functional abilities in children with hemophilia. PedHAL will be obtained and compared in study participants on efanesoctocog alfa or emicizumab

    Time frame: From enrollment, every 6 months, until 3 years

  4. Health related quality of life - CATCH

    CATCH (Comprehensive Assessment Tool of Challenges in Hemophilia) is a validated, multi-version patient-reported outcome instrument designed to assess the real-world impact of hemophilia on individuals and their caregivers. CATCH will be obtained and compared in study participants on efanesoctocog alfa or emicizumab

    Time frame: From enrollment, every 6 months, until 3 years

  5. Joint Tissue Changes

    Point-of-care ultrasound using JADE protocol to evaluate joint tissue changes will be obtained and compared in study participants on efanesoctocog alfa or emicizumab

    Time frame: From enrollment, every 6 months, until 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2033, 82 months after the start.

Of 78 non-industry observational studies under Hemophilia A, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 96. This study's planned 82 months is above that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jul 9, 2026
StartActual
Jul 22, 2026
Primary completionEst.
May 2033
CompletionEst.
May 2033
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
The University of Texas Southwestern Medical Center is now Recruiting
Sep 29, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameHemophilia Joint Health ScoreObtained at baseline and every 6 months → Obtained at baseline and every 6 months, until 3 years
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    The University of Texas Southwestern Medical Center is now Recruiting
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameHemophilia Joint Health ScoreObtained at baseline and every 6 months → Obtained at baseline and every 6 months, until 3 years
    + 3 other changes: verification date, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07692217
Collaborators
Sanofi
Responsible party
Jessica Garcia (Assistant Professor of Pediatrics, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jul 9, 2026
Start date
Jul 22, 2026
Primary completion
May 2033 (estimated)
Completion
May 2033 (estimated)
Last update
Sep 29, 2026

Study contacts

Jessica Garcia, MD
Contact
Jessica.Garcia@UTSouthwestern.edu
214-456-7000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion